RS-2023-00258166

Retinal regenerative antibody and gene therapy

Celliaz Ltd.

OPHTHALMOLOGY | Hit

Product Type	Antibody Protein and Gene Therapy
Indication	Retinal regeneration
Target	PROX1
MoA(Mechanism of Action)	Blocking the transfer of PROX1 to Müller glia by sequestering it in the extracellular space, consequently promoting the regeneration of retinal cells from the Müller glia
Competitiveness	Current therapies for retinal diseases can delay the worsening of the symptoms, but cannot recover degenerated retinal cells. The structural and functional recovery of the disease retina can only be achieved by regenerative therapy. The recovery of endogenous regenerative potential of the disease retina can meet the unmet need of the disease therapeutics.
Development Stage	Hit(Identification of a valid drug candidate)
Route of Administration	Intravitreal delivery of the antibody protein or gene

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund